Creative Dance-Supported CO-OP Approach in Older Adults With Mild Cognitive Impairment

Launched by ÇANKIRI KARATEKIN UNIVERSITY · Oct 15, 2024

Keywords

ClinConnect Summary

This clinical trial is looking to see if a special approach called CO-OP (Cognitive Orientation to daily Occupational Performance), when combined with creative dance, can help improve thinking skills in older adults with mild cognitive impairment (MCI). MCI can affect memory, attention, and the ability to carry out daily tasks. The study will compare two groups of participants: one will participate in CO-OP alone, while the other will take part in CO-OP along with creative dance for eight weeks. Researchers want to find out if the dance helps improve skills like memory and attention more than CO-OP by itself.

To be eligible for this study, participants need to be between 65 and 85 years old and have a diagnosis of mild cognitive impairment. They should be able to participate in physical activities, like dance, and be willing to attend all sessions. However, those with more serious cognitive issues, certain physical impairments, or specific mental health conditions may not be eligible. Participants can expect to engage in fun cognitive tasks and dance activities, all while learning how to better manage their daily lives. This trial is not yet recruiting, but it aims to provide valuable insights into how creative movements might support cognitive health in older adults.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 65 and 85 years old
• • Diagnosis of mild cognitive impairment (MCI) according to DSM-5 criteria
• • Ability to participate in physical activities, including creative dance movements
• • Willingness to attend all study sessions and follow-up assessments
• • Able to give informed consent
• Exclusion Criteria:
• • Diagnosis of a major neurocognitive disorder (e.g., Alzheimer's disease)
• • Presence of severe physical impairments that prevent participation in physical activity
• • Current use of medications that significantly affect cognitive function
• • Participation in another clinical trial within the past 3 months
• • History of significant psychiatric disorders (e.g., major depression, schizophrenia)